Arrhythmic risk stratification in patients with dilated cardiomyopathy and intermediate left ventricular dysfunction.


Journal

Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752

Informations de publication

Date de publication:
May 2019
Historique:
entrez: 29 3 2019
pubmed: 29 3 2019
medline: 29 5 2019
Statut: ppublish

Résumé

Arrhythmic risk stratification is a challenging issue in patients with dilated cardiomyopathy (DCM), particularly when left ventricular ejection fraction (LVEF) is more than 35%. We studied the prevalence and predictors of sudden cardiac death or malignant ventricular arrhythmias (SCD/MVAs) in DCM patients categorized at low arrhythmic risk because of intermediate left ventricular dysfunction under optimal medical treatment (OMT). DCM patients considered at low arrhythmic risk (LVEF >35% and New York Heart Association class I-III after 6 ± 3 months of OMT) were analysed. An arrhythmogenic profile was defined as the presence of at least one among a history of syncope, nonsustained ventricular tachycardia, at least 1000 premature ventricular contractions/24 h, at least 50 ventricular couplets/24 h at Holter ECG monitoring. SCD/MVAs was considered as the study end-point. During a median follow-up of 152 months (interquartile range 100-234), 30 out of 360 (8.3%) patients at low arrhythmic risk (LVEF 47 ± 7%) experienced the study end-point [14 (3.9%) SCD and 16 (4.4%) MVA]. Compared with survivors, patients who experienced SCD/MVAs had more frequently an arrhythmogenic profile and a larger left atrium. Their LVEF at the last available evaluation before the arrhythmic event was 36 ± 12%. At multivariable analysis, left atrial end-systolic area [hazard ratio 1.107; 95% confidence interval (95% CI) 1.039-1.179, P = 0.002 for 1 mm increase] and arrhythmogenic profile (hazard ratio 3.667; 95% CI 1.762-7.632, P = 0.001) emerged as predictors of SCD/MVAs during follow-up. A consistent quota of DCM patients with intermediate left ventricular dysfunction receiving OMT experienced SCD/MVA during follow-up. Left atrial dilatation and arrhythmogenic pattern were associated with a higher risk of SCD/MVA.

Identifiants

pubmed: 30921270
doi: 10.2459/JCM.0000000000000792
pii: 01244665-201905000-00011
doi:

Substances chimiques

Cardiovascular Agents 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-350

Auteurs

Marco Merlo (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Piero Gentile (P)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Jessica Artico (J)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Antonio Cannatà (A)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Alessia Paldino (A)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Giulia De Angelis (G)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Giulia Barbati (G)

Biostatistics Unit, Department of Medical Sciences, University of Trieste, Trieste, Italy.

Marco Alonge (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Marta Gigli (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Bruno Pinamonti (B)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Federica Ramani (F)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Massimo Zecchin (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Fabrizio Pirozzi (F)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Davide Stolfo (D)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Gianfranco Sinagra (G)

Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH